Currently, numerous clinical trials are underway to explore the therapeutic potential of CD123-targeted BiTEs, focusing on their safety, tolerability, and anti-tumor effectiveness [46,47,48] (Figure 3). This evidence concerns the gene IL3RA and neoplasm.